Our findings suggest that miR-224 acts as a tumor promoter in cervical cancer, and that miR-224 and its target RASSF8 protein have potential for use as prognostic predictors or therapeutic targets in cervical cancer patients. This evidence concerns the gene RASSF8 and cervical carcinoma.